On the contrary, the golden hamster model manifests a much more severe form of the disease, accompanied by rapid weight loss and severe lung pathology ( 21– 23). The rhesus macaque model is widely used to assess efficacy of therapeutics and vaccines and displays a transient and mild course of the disease ( 13– 20). Indeed, based on the extremely diverse manifestations of COVID-19 in humans, multiple animal models may be needed to mimic various settings of human infection. Furthermore, because the animal models of SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) are still being developed, no single model has emerged as being more relevant for human disease. However, evaluation of the efficacy of these antibodies in vivo is only beginning to emerge and has largely focused on the prophylactic setting ( 6, 10, 12). To date, multiple studies have described the discovery and characterization of potent neutralizing mAbs targeting the spike glycoprotein of SARS-CoV-2 ( 2– 11). Fully human monoclonal antibodies (mAbs) are a promising class of therapeutics against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection ( 1).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |